Plus Therapeutics Inc Total Assets
Plus Therapeutics Inc total assets. Based on the latest financial reports, Plus Therapeutics Inc (PSTV) holds total assets worth $14.03 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Plus Therapeutics Inc worth for the company's overall valuation and market capitalisation.
Total Assets of Plus Therapeutics Inc (1998–2025)
Total assets of Plus Therapeutics Inc from 1998 to 2025. This chart illustrates how Plus Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See today's stock price for Plus Therapeutics Inc for real-time trading data and today's change.
Plus Therapeutics Inc - Asset Composition Analysis
Plus Therapeutics Inc Total Assets Breakdown (December 2025)
Plus Therapeutics Inc total assets breakdown as of December 2025. Plus Therapeutics Inc's total assets of $14.03 Million consist of 92.9% current assets and 7.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 53.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $333.00K | 2.0% |
| Goodwill | $372.00K | 2.3% |
Asset Composition Trend (1998–2025)
This chart illustrates how Plus Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Plus Therapeutics Inc current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Plus Therapeutics Inc's current assets represent 92.9% of total assets in 2025, an increase from 3.4% in 1998.
- Cash Position: Cash and equivalents constituted 53.7% of total assets in 2025, up from 3.4% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 2.3% of total assets.
Plus Therapeutics Inc Competitors by Total Assets
Key competitors of Plus Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Plus Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.37 | 1.26 | 2.33 |
| Quick Ratio | 1.37 | 1.26 | 2.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.20 Million | $1.90 Million | $12.61 Million |
Plus Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Plus Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.14 |
| Latest Market Cap to Assets Ratio | 1.62 |
| Asset Growth Rate (YoY) | 146.1% |
| Total Assets | $16.32 Million |
| Market Capitalization | $26.42 Million USD |
Valuation Analysis
Above Book Valuation: The market values Plus Therapeutics Inc's assets above their book value (1.62x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Plus Therapeutics Inc's assets grew by 146.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Plus Therapeutics Inc (1998–2025)
The table below shows the annual total assets of Plus Therapeutics Inc from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $16.32 Million | +146.12% |
| 2024-12-31 | $6.63 Million | -41.75% |
| 2023-12-31 | $11.39 Million | -52.29% |
| 2022-12-31 | $23.87 Million | +8.58% |
| 2021-12-31 | $21.98 Million | +81.59% |
| 2020-12-31 | $12.11 Million | -47.89% |
| 2019-12-31 | $23.23 Million | -3.18% |
| 2018-12-31 | $23.99 Million | -24.12% |
| 2017-12-31 | $31.61 Million | -8.65% |
| 2016-12-31 | $34.61 Million | -8.19% |
| 2015-12-31 | $37.70 Million | -2.64% |
| 2014-12-31 | $38.72 Million | -7.94% |
| 2013-12-31 | $42.06 Million | -2.75% |
| 2012-12-31 | $43.25 Million | -16.07% |
| 2011-12-31 | $51.53 Million | -22.33% |
| 2010-12-31 | $66.35 Million | +168.08% |
| 2009-12-31 | $24.75 Million | -3.36% |
| 2008-12-31 | $25.61 Million | +19.07% |
| 2007-12-31 | $21.51 Million | -13.52% |
| 2006-12-31 | $24.87 Million | -11.71% |
| 2005-12-31 | $28.17 Million | +10.59% |
| 2004-12-31 | $25.47 Million | -9.32% |
| 2003-12-31 | $28.09 Million | -28.56% |
| 2002-12-31 | $39.32 Million | -8.86% |
| 2001-12-31 | $43.14 Million | -17.46% |
| 2000-12-31 | $52.27 Million | +837.56% |
| 1999-12-31 | $5.58 Million | +446.57% |
| 1998-12-31 | $1.02 Million | -- |
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric br… Read more